사용자:YounYoungShim/연습장
Linusorb[편집]
Flaxseed synthesizes an array of biologically active cyclic peptides or linusorbs (LOs) from two ribosome-derived precursors. The International Union of Pure and Applied Chemistry (IUPAC) Nomenclature for Natural Products supports the use of taxonomic names for the development of compound trivial names, while UniProt utilizes standard organism names as well as organism mnemonics in the naming of proteins. Linusirb product name according to Shim et al. (2015).[1]
[1–#-NαC],[#-Xaa,#-Xaa]-linusorb # [편집]
Linkage [1–#-NαC]. Occurs between amino acid 1 and amino acid “#” through the α-amino group that a N-C cyclization of the core peptide. The en dash (–) is used and placed in square brackets.
Modifications [#-Xaa,#-Xaa]. The notation utilizes a prefix code of 3, 4 characters. Specifies the position and type of modified amino acid(s) in the peptide. Each modified amino acid is identified by its position in the core peptide sequence using abbreviations found in UniProt and IUPAC. A comma separates multiple post-translational modifications.
Taxonomic name abbreviation -linus. The first three letters of the genus name and first two letters of the species name are used to identify the origin of the orbitide. Based on the list of species maintained by UniProt (http://www.uniprot.org/docs/speclist).
Common suffix (-orb). Short for orbitide.
Amino acid residue numbering (#). Residue numbering begins at the N-terminal-most amino acid residue of the orbitide, based on DNA sequence. Notation for any post-translational modifications start with the lowest number and proceed to the highest number. Where multiple identical modifications are present, they are grouped together as illustrated for Met groups in [1–8-NαC],[1,3-(Rs,Ss)-MetO]-linusorb A1 (Table 1 and Figure 1; formerly cyclolinopeptide G, CLG). This more descriptive name for CLG reflects the complexity of fully and appropriately naming this compound as it contains the chiral amino acid methionine S-oxide. Clearly, what was formerly recognized as CLG is actually four distinct compounds. New full names for all “cyclolinopeptide” variants are suggested in Table 1.
Table 1. Elements of Linusorb Names
| Proposed linusorb namea | Literature nameb (code) | Amino acid sequence (NαC-)c | Gene |
| [1–8-NαC]-linusorb A1 | CLM (1) | Met-Leu-Met-Pro-Phe-Phe-Trp-Ile | AFSQ01025165.1 |
| [1–8-NαC],[1-(Rs)-MetO]-linusorb A1 | [(Rs)-MetO]-Leu-Met-Pro-Phe-Phe-Trp-Ile | ||
| [1–8-NαC],[1-(Ss)-MetO]-linusorb A1 | [(Ss)-MetO]-Leu-Met-Pro-Phe-Phe-Trp-Ile | ||
| [1–8-NαC],[1-(Rs,Ss)-MetO]-linusorb A1 | CLH (2) | [(Rs,Ss)-MetO]-Leu-Met-Pro-Phe-Phe-Trp-Ile | |
| [1–8-NαC],[3-(Rs)-MetO]-linusorb A1 | Met-Leu-[(Rs)-MetO]-Pro-Phe-Phe-Trp-Ile | ||
| [1–8-NαC],[3-(Ss)-MetO]-linusorb A1 | Met-Leu-[(Ss)-MetO]-Pro-Phe-Phe-Trp-Ile | ||
| [1–8-NαC],[3-(Rs,Ss)-MetO]-linusorb A1 | CLN (3) | Met-Leu-[(Rs,Ss)-MetO]-Pro-Phe-Phe-Trp-Ile | |
| [1–8-NαC],[1,3-(Rs,Rs)-MetO]-linusorb A1 | [(Rs)-MetO]-Leu-[(Rs)-MetO]-Pro-Phe-Phe-Trp-Ile | ||
| [1–8-NαC],[1,3-(Ss,Ss)-MetO]-linusorb A1 | [(Ss)-MetO]-Leu-[(Ss)-MetO]-Pro-Phe-Phe-Trp-Ile | ||
| [1–8-NαC],[1-(Rs)-MetO,3-(Ss)-MetO]-linusorb A1 | [(Rs)-MetO]-Leu-[(Ss)-MetO]-Pro-Phe-Phe-Trp-Ile | ||
| [1–8-NαC],[1-(Ss)-MetO,3-(Rs)-MetO]-linusorb A1 | [(Ss)-MetO]-Leu-[(Rs)-MetO]-Pro-Phe-Phe-Trp-Ile | ||
| [1–8-NαC],[1,3-(Rs,Ss)-MetO]-linusorb A1 | CLG (4) | [(Rs,Ss)-MetO]-Leu-[(Rs,Ss)-MetO]-Pro-Phe-Phe-Trp-Ile | |
| [1–8-NαC]-linusorb A2 | CLO (5) | Met-Leu-Leu-Pro-Phe-Phe-Trp-Ile | |
| [1–8-NαC],[1-(Rs)-MetO]-linusorb A2 | [(Rs)-MetO]-Leu-Leu-Pro-Phe-Phe-Trp-Ile | ||
| [1–8-NαC],[1-(Ss)-MetO]-linusorb A2 | [(Ss)-MetO]-Leu-Leu-Pro-Phe-Phe-Trp-Ile | ||
| [1–8-NαC],[1-(Rs,Ss)-MetO]-linusorb A2 | CLD (6) | [(Rs,Ss)-MetO]-Leu-Leu-Pro-Phe-Phe-Trp-Ile | |
| [1–8-NαC],[1-MetO2]-linusorb A2 | 1-Msn-CLD (7) | MetO2-Leu-Leu-Pro-Phe-Phe-Trp-Ile | |
| [1–8-NαC]-linusorb A3 | CLL (8) | Met-Leu-Met-Pro-Phe-Phe-Trp-Val | |
| [1–8-NαC],[1-(Rs)-MetO]-linusorb A3 | [(Rs)-MetO]-Leu-Met-Pro-Phe-Phe-Trp-Val | ||
| [1–8-NαC],[1-(Ss)-MetO]-linusorb A3 | [(Ss)-MetO]-Leu-Met-Pro-Phe-Phe-Trp-Val | ||
| [1–8-NαC],[1-(Rs,Ss)-MetO]-linusorb A3 | [1–8-NαC],[1-MetO]-CLF (9) | [(Rs,Ss)-MetO]-Leu-Met-Pro-Phe-Phe-Trp-Val | |
| [1–8-NαC],[3-(Rs)-MetO]-linusorb A3 | Met-Leu-[(Rs)-MetO]-Pro-Phe-Phe-Trp-Val | ||
| [1–8-NαC],[3-(Ss)-MetO]-linusorb A3 | Met-Leu-[(Ss)-MetO]-Pro-Phe-Phe-Trp-Val | ||
| [1–8-NαC],[3-(Rs,Ss)-MetO]-linusorb A3 | CLI (10) | Met-Leu-[(Rs,Ss)-MetO]-Pro-Phe-Phe-Trp-Val | |
| [1–8-NαC],[1-(Rs)-MetO,3-(Rs)-MetO]-linusorb A3 | [(Rs)-MetO]-Leu-[(Rs)-MetO]-Pro-Phe-Phe-Trp-Val | ||
| [1–8-NαC],[1-(Ss)-MetO,3-(Ss)-MetO]-linusorb A3 | [(Ss)-MetO]-Leu-[(Ss)-MetO]-Pro-Phe-Phe-Trp-Val | ||
| [1–8-NαC],[1-(Rs)-MetO,3-(Ss)-MetO]-linusorb A3 | [(Rs)-MetO]-Leu-[(Ss)-MetO]-Pro-Phe-Phe-Trp-Val | ||
| [1–8-NαC],[1-(Ss)-MetO,3-(Rs)-MetO]-linusorb A3 | [(Ss)-MetO]-Leu-[(Rs)-MetO]-Pro-Phe-Phe-Trp-Val | ||
| [1–8-NαC],[1,3-(Rs,Ss)-MetO]-linusorb A3 | CLF (11) | [(Rs,Ss)-MetO]-Leu-[(Rs,Ss)-MetO]-Pro-Phe-Phe-Trp-Val | |
| [1–8-NαC]-linusorb B1 | CLP (12) | Met-Leu-Val-Phe-Pro-Leu-Phe-Ile | AFSQ01016651.1 |
| [1–8-NαC],[1-(Rs)-MetO]-linusorb B1 | [(Rs)-MetO]-Leu-Val-Phe-Pro-Leu-Phe-Ile | ||
| [1–8-NαC],[1-(Ss)-MetO]-linusorb B1 | [(Ss)-MetO]-Leu-Val-Phe-Pro-Leu-Phe-Ile | ||
| [1–8-NαC],[1-(Rs,Ss)-MetO]-linusorb B1 | CLE (13) | [(Rs,Ss)-MetO]-Leu-Val-Phe-Pro-Leu-Phe-Ile | |
| [1–8-NαC],[1-MetO2]-linusorbB1 | CLJ (14) | MetO2-Leu-Val-Phe-Pro-Leu-Phe-Ile | |
| [1–9-NαC]-linusorb B2 | CLB (15) | Met-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile | |
| [1–9-NαC],[1-(Rs)-MetO]-linusorb B2 | [(Rs)-MetO]-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile | ||
| [1–9-NαC],[1-(Ss)-MetO]-linusorb B2 | [(Ss)-MetO]-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile | ||
| [1–9-NαC],[1-(Rs,Ss)-MetO]-linusorb B2 | CLC (16) | [(Rs,Ss)-MetO]-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile | |
| [1–9-NαC],[1-MetO2]-linusorb B2 | CLK (17) | MetO2-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile | |
| [1–9-NαC]-linusorb B3 | CLA (18) | Ile-Leu-Val-Pro-Pro-Phe-Phe-Leu-Ile | |
| [1–9-NαC]-linusorb C1 | [1–9-NαC]-CLQ (19) | Met-Leu-Lys-Pro-Phe-Phe-Phe-Trp-Ile | gened |
| [1–9-NαC],[1-(Rs,Ss)-MetO]-linusorb C1 | [1–9-NαC],[1-MetO]-CLQ (20) | [(Rs,Ss)-MetO]-Leu-Lys-Pro-Phe-Phe-Phe-Trp-Ile | |
| [1–9-NαC]-linusorb D1 | [1–9-NαC]-CLS (21) | Gly-Ile-Pro-Pro-Phe-Trp-Leu-Thr-Leu | genese |
| [1–9-NαC]-linusorb E1 | [1–9-NαC]-CLX (22) | Gly-Met-Leu-Val-Phe-Pro-Leu-Phe-Ile | genef |
| [1–9-NαC],[2-(Rs,Ss)-MetO]-linusorb E1 | [1–9-NαC],[2-MetO]-CLX (23) | Gly-[(Rs,Ss)-MetO]-Leu-Val-Phe-Pro-Leu-Phe-Ile | |
| [1–9-NαC],[2-MetO2]-linusorb E1 | (24) | Gly-MetO2-Leu-Val-Phe-Pro-Leu-Phe-Ile | |
| [1–10-NαC]-linusorb E2 | [1–10-NαC]-CLV (25) | Gly-Met-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile | |
| [1–10-NαC],[2-(Rs,Ss)-MetO]-linusorb E2 | [1–10-NαC],[2-MetO]-CLV (26) | Gly-[(Rs,Ss)-MetO]-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile | |
| [1–10-NαC],[2-MetO2]-linusorb E2 | (27) | Gly-MetO2-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile | |
| [1–10-NαC]-linusorb E3 | [1–10-NαC]-CLU (28) | Gly-Ile-Leu-Val-Pro-Pro-Phe-Phe-Leu-Ile |
-
Figure 1. Structures of linusorbs A−E
Cyclization[편집]
Linusorbs are small peptides with both ends joined to form a circle. This cyclization results in small molecules that are very stable, not easily metabolized and very rigid in structure.[2]
- ↑ Shim, Youn Young; Young, Lester W.; Arnison, Paul G.; Gilding, Edward; Reaney, Martin J. T. (2015년 4월 24일). “Proposed Systematic Nomenclature for Orbitides”. 《Journal of Natural Products》 78 (4): 645–652. doi:10.1021/np500802p. ISSN 0163-3864.
- ↑ YY Shim, Youn Young Shim. “Linusorbs by Prairie Tide Chemicals”.